Collaborative science in action: A 20 year perspective from the Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee

IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Jennifer B. Pierson , Brian Berridge , Ksenia Blinova , Marjory B. Brooks , Sandy Eldridge , Claire E. O'Brien , Michael K. Pugsley , A. Eric Schultze , Godfrey Smith , Norman Stockbridge , Jean-Pierre Valentin , Jose Vicente
{"title":"Collaborative science in action: A 20 year perspective from the Health and Environmental Sciences Institute (HESI) Cardiac Safety Committee","authors":"Jennifer B. Pierson ,&nbsp;Brian Berridge ,&nbsp;Ksenia Blinova ,&nbsp;Marjory B. Brooks ,&nbsp;Sandy Eldridge ,&nbsp;Claire E. O'Brien ,&nbsp;Michael K. Pugsley ,&nbsp;A. Eric Schultze ,&nbsp;Godfrey Smith ,&nbsp;Norman Stockbridge ,&nbsp;Jean-Pierre Valentin ,&nbsp;Jose Vicente","doi":"10.1016/j.vascn.2024.107511","DOIUrl":null,"url":null,"abstract":"<div><p>The Health and Environmental Sciences Institute (HESI) is a nonprofit organization dedicated to resolving global health challenges through collaborative scientific efforts across academia, regulatory authorities and the private sector. Collaborative science across non-clinical disciplines offers an important keystone to accelerate the development of safer and more effective medicines. HESI works to address complex challenges by leveraging diverse subject-matter expertise across sectors offering access to resources, data and shared knowledge. In 2008, the HESI Cardiac Safety Committee (CSC) was established to improve public health by reducing unanticipated cardiovascular (CV)-related adverse effects from pharmaceuticals or chemicals. The committee continues to significantly impact the field of CV safety by bringing together experts from across sectors to address challenges of detecting and predicting adverse cardiac outcomes. Committee members have collaborated on the organization, management and publication of prospective studies, retrospective analyses, workshops, and symposia resulting in 38 peer reviewed manuscripts. Without this collaboration these manuscripts would not have been published. Through their work, the CSC is actively addressing challenges and opportunities in detecting potential cardiac failure modes using <em>in vivo</em>, <em>in vitro</em> and <em>in silico</em> models, with the aim of facilitating drug development and improving study design. By examining past successes and future prospects of the CSC, this manuscript sheds light on how the consortium's multifaceted approach not only addresses current challenges in detecting potential cardiac failure modes but also paves the way for enhanced drug development and study design methodologies. Further, exploring future opportunities and challenges will focus on improving the translational predictability of nonclinical evaluations and reducing reliance on animal research in CV safety assessments.</p></div>","PeriodicalId":16767,"journal":{"name":"Journal of pharmacological and toxicological methods","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1056871924000212/pdfft?md5=89f923b770a666d0bb1b5e0e5b6bd9c2&pid=1-s2.0-S1056871924000212-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacological and toxicological methods","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1056871924000212","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The Health and Environmental Sciences Institute (HESI) is a nonprofit organization dedicated to resolving global health challenges through collaborative scientific efforts across academia, regulatory authorities and the private sector. Collaborative science across non-clinical disciplines offers an important keystone to accelerate the development of safer and more effective medicines. HESI works to address complex challenges by leveraging diverse subject-matter expertise across sectors offering access to resources, data and shared knowledge. In 2008, the HESI Cardiac Safety Committee (CSC) was established to improve public health by reducing unanticipated cardiovascular (CV)-related adverse effects from pharmaceuticals or chemicals. The committee continues to significantly impact the field of CV safety by bringing together experts from across sectors to address challenges of detecting and predicting adverse cardiac outcomes. Committee members have collaborated on the organization, management and publication of prospective studies, retrospective analyses, workshops, and symposia resulting in 38 peer reviewed manuscripts. Without this collaboration these manuscripts would not have been published. Through their work, the CSC is actively addressing challenges and opportunities in detecting potential cardiac failure modes using in vivo, in vitro and in silico models, with the aim of facilitating drug development and improving study design. By examining past successes and future prospects of the CSC, this manuscript sheds light on how the consortium's multifaceted approach not only addresses current challenges in detecting potential cardiac failure modes but also paves the way for enhanced drug development and study design methodologies. Further, exploring future opportunities and challenges will focus on improving the translational predictability of nonclinical evaluations and reducing reliance on animal research in CV safety assessments.

行动中的合作科学:健康与环境科学研究所(HESI)心脏安全委员会的 20 年展望。
健康与环境科学研究所(HESI)是一家非营利性组织,致力于通过学术界、监管机构和私营部门的科学合作来解决全球健康难题。跨非临床学科的合作科学是加快开发更安全、更有效药物的重要基石。HESI 致力于利用跨部门的不同学科专业知识,提供资源、数据和共享知识,以应对复杂的挑战。2008 年,成立了 HESI 心脏安全技术委员会 (CSTC),旨在通过减少与心血管 (CV) 相关的药品或化学品的意外不良反应来改善公众健康。该委员会汇集了来自各行各业的专家,共同应对检测和预测不良心脏结果的挑战,从而继续对心血管安全领域产生重大影响。委员会成员在前瞻性研究、回顾性分析、研讨会和专题讨论会的组织、管理和出版方面进行了合作,共发表了 38 篇经同行评审的手稿。如果没有这些合作,这些手稿将无法发表。通过他们的工作,CSTC 正在积极应对使用体内、体外和硅学模型检测潜在心力衰竭模式的挑战和机遇,目的是促进药物开发和改进研究设计。通过研究 CSTC 过去的成功和未来的前景,本手稿揭示了该联盟的多层面方法如何不仅应对当前检测潜在心衰模式的挑战,而且还为加强药物开发和研究设计方法铺平了道路。此外,探索未来的机遇和挑战将侧重于提高非临床评估的转化可预测性,并减少心血管安全性评估对动物研究的依赖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of pharmacological and toxicological methods
Journal of pharmacological and toxicological methods PHARMACOLOGY & PHARMACY-TOXICOLOGY
CiteScore
3.60
自引率
10.50%
发文量
56
审稿时长
26 days
期刊介绍: Journal of Pharmacological and Toxicological Methods publishes original articles on current methods of investigation used in pharmacology and toxicology. Pharmacology and toxicology are defined in the broadest sense, referring to actions of drugs and chemicals on all living systems. With its international editorial board and noted contributors, Journal of Pharmacological and Toxicological Methods is the leading journal devoted exclusively to experimental procedures used by pharmacologists and toxicologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信